SSY GROUP Receives Regulatory Approval for Ziprasidone Mesylate as API for Commercial Pharmaceutical Use

Stock News

昨天

SSY GROUP (stock code: 02005) has announced that its Ziprasidone Mesylate has been granted registration approval by China's National Medical Products Administration, enabling its use as an active pharmaceutical ingredient (API) in marketed drug formulations.

This API is primarily indicated for treating acute agitation symptoms in patients with schizophrenia. The newly obtained approval further strengthens the company's portfolio of second-generation antipsychotic high-potency active pharmaceutical ingredients (HPAPI).

Currently, the group has established a leading domestic platform for second-generation antipsychotic HPAPIs, encompassing Blonanserin, Lurasidone, Ziprasidone Hydrochloride, and the newly approved Ziprasidone Mesylate. This development consistently provides robust supply chain support for domestic pharmaceutical manufacturers seeking high-quality APIs.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1137116463"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137116463\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1137116463?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-16 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137116463","market":"sg","top_or_hot":-1,"title":"SSY GROUP Receives Regulatory Approval for Ziprasidone Mesylate as API for Commercial Pharmaceutical Use","media":"Stock News","content":"<p><b>SSY GROUP</b> (<b>stock code: 02005</b>) has announced that its Ziprasidone Mesylate has been granted registration approval by China's National Medical Products Administration, enabling its use as an active pharmaceutical ingredient (API) in marketed drug formulations.<br><br>This API is primarily indicated for treating acute agitation symptoms in patients with schizophrenia. The newly obtained approval further strengthens the company's portfolio of second-generation antipsychotic high-potency active pharmaceutical ingredients (HPAPI).<br><br>Currently, the group has established a leading domestic platform for second-generation antipsychotic HPAPIs, encompassing Blonanserin, Lurasidone, Ziprasidone Hydrochloride, and the newly approved Ziprasidone Mesylate. This development consistently provides robust supply chain support for domestic pharmaceutical manufacturers seeking high-quality APIs.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SSY GROUP Receives Regulatory Approval for Ziprasidone Mesylate as API for Commercial Pharmaceutical Use</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSSY GROUP Receives Regulatory Approval for Ziprasidone Mesylate as API for Commercial Pharmaceutical Use\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-09-16 17:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><b>SSY GROUP</b> (<b>stock code: 02005</b>) has announced that its Ziprasidone Mesylate has been granted registration approval by China's National Medical Products Administration, enabling its use as an active pharmaceutical ingredient (API) in marketed drug formulations.<br><br>This API is primarily indicated for treating acute agitation symptoms in patients with schizophrenia. The newly obtained approval further strengthens the company's portfolio of second-generation antipsychotic high-potency active pharmaceutical ingredients (HPAPI).<br><br>Currently, the group has established a leading domestic platform for second-generation antipsychotic HPAPIs, encompassing Blonanserin, Lurasidone, Ziprasidone Hydrochloride, and the newly approved Ziprasidone Mesylate. This development consistently provides robust supply chain support for domestic pharmaceutical manufacturers seeking high-quality APIs.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"製藥","start_time":0,"source_url":"","article_id":"1137116463","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137116463","pubTimestamp":1789549471,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SSY GROUP (stock code: 02005) has announced that its Ziprasidone Mesylate has been granted registration approval by China's National Medical Products Administration, enabling its use as an active...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","LU2460026573.USD":"abrdn SICAV I -  CHINA NEXT GENERATION \"A\" (USD) ACC","02005":"石四药集团","IPOS":"Renaissance International IPO ETF"},"translate_title":"SSY集团甲磺酸齐拉西酮作为商业制药原料药获得监管部门批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02005":1,"IPOS":1},"content_text":"SSY GROUP (stock code: 02005) has announced that its Ziprasidone Mesylate has been granted registration approval by China's National Medical Products Administration, enabling its use as an active pharmaceutical ingredient (API) in marketed drug formulations.This API is primarily indicated for treating acute agitation symptoms in patients with schizophrenia. The newly obtained approval further strengthens the company's portfolio of second-generation antipsychotic high-potency active pharmaceutical ingredients (HPAPI).Currently, the group has established a leading domestic platform for second-generation antipsychotic HPAPIs, encompassing Blonanserin, Lurasidone, Ziprasidone Hydrochloride, and the newly approved Ziprasidone Mesylate. This development consistently provides robust supply chain support for domestic pharmaceutical manufacturers seeking high-quality APIs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}